Mini Review
Volume 4 Issue 6 - 2020
Graves’ Disease: Analytical Methods to Determine Antithyroid Therapeutic Agents in Biological Fluids
Chika J Mbah*
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria
*Corresponding Author: Chika J Mbah, Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria.
Received: May 17, 2020; Published: May 25, 2020


Graves’ disease is an autoimmune disease arising from antibodies that attach to receptors on thyroid hormone-producing cells in the thyroid gland triggering off over production of thyroid hormone. The most important diagnostic tests for Graves’ disease are measurements of serum levels of anti-TSH-receptor antibodies (TRAb) and thyroid ultrasonography. Clinical management of the disease involves the use antithyroid drugs, which mainly inhibit synthesis of thyroid hormone, or ablative treatments (iodine 131-radiotherapy or thyroidectomy) that remove or reduce thyroid tissue. Though these treatments do not target the disease process, however new agents blocking the thyrotropin and insulin-like growth factor receptors are under evaluation in preclinical or clinical studies for such purpose. Of all the analytical methods such as spectroscopy, electrochemical, electrophoresis and chromatography that have been used to determine antithyroid therapeutic agents (drugs) in biological fluids, high performance liquid chromatography seems to be the analytical method of choice.

Keywords: Graves’ Disease; Antithyroid Drugs; Biological Fluids; Analytical Methods


  1. Bartalena L and Tanda M L. “Clinical practice. Graves’ ophthalmopathy”. New England Journal Medicine 360 (2009): 994-1001.
  2. Tanda ML., et al. “Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center”. Journal Clinical Endocrinology Metabolism 98 (2013): 1443-1449.
  3. Piantanida E., et al. “Prevalence and natural history of Graves’ orbitopathy in the XXI century”. Journal Endocrinology Investigation 36 (2013): 444-449.
  4. Fatourechi V. “Thyroid dermopathy and acropachy”. Best Practice Research Clinical Endocrinology Metabolism 26 (2012): 553-565.
  5. Weetman AP. “Graves’ disease”. New England Journal Medicine 343 (2000): 1236-1248.
  6. Prabhakar BS., et al. “Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy”. Endocrine Review 24 (2003): 802-835.
  7. Brix TH., et al. “Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts”. Journal Clinical Endocrinology Metabolism 86 (2001): 930-934.
  8. Brand OJ and Gough SCL. “Genetics of thyroid autoimmunity and the role of the TSHR”. Molecular Cellular Endocrinology 322 (2010): 135-143.
  9. Morshed SA., et al. “Delineating the autoimmune mechanisms in Graves’ disease”. Immunology Research 54 (2012): 191-203.
  10. Boelaert K., et al. “Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study”. Journal Clinical Endocrinology Metabolism 95 (2010): 2715-2726.
  11. Burch HB., et al. “A 2011 survey of clinical practice patterns in the management of Graves’ disease”. Journal Clinical Endocrinology Metabolism 97 (2012): 4549-4558.
  12. Bahn RS., et al. “Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists”. Thyroid 21 (2011): 593-646.
  13. , et al. “Evaluation of a new rapid and fully automated electroluminescence immunoassay for thyrotropin receptor autoantibodies”. Thyroid 18 (2008): 1157-1164.
  14. Schott M., et al. “Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves’ disease (GD): an international multicentre trial”. Clinical Endocrinology 71 (2009): 566-573.
  15. Bartalena L. “Diagnosis and management of Graves disease: a global overview”. Nature Reviews Endocrinology 9 (2013): 724-734.
  16. Weetman AP. “How antithyroid drugs work in Graves’ disease”. Clinical Endocrinology 37 (1992): 317-318.
  17. Cooper DS. “Antithyroid drugs”. New England Journal Medicine 352 (2005): 905-917.
  18. Abraham P., et al. “Antithyroid drug regimen for treating Graves’ hyperthyroidism”. Cochrane Database of Systematic Reviews 1 (2004): CD003420.
  19. Karlsson F., et al. “Severe embriopathy and exposure to methimazole in early pregnancy”. Journal Clinical Endocrinology Metabolism 87 (2001): 947-948.
  20. Foulds N., et al. “Carbimazole embryopathy: an emerging phenotype”. American Journal Medical Genetics A 132A (2005): 130-135.
  21. Ross DS. “Radioiodine therapy for hyperthyroidism”. New England Journal Medicine 364 (2011): 542-550.
  22. Vaidya B., et al. “Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists”. Clinical Endocrinology 68 (2008): 814-820.
  23. Genovese BM., et al. “What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature”. Annal Surgery Oncology 20 (2013): 660-667.
  24. Grodski S., et al. “Surgery versus radioiodine therapy as definitive management for Graves’ disease: the role of patient preference”. Thyroid 17 (2007): 157-160.
  25. Gibaldi M. “Biopharmaceutics and Clinical Pharmacokinetics”, Fourth Edition, Lea nd Febiger, Philadelphia (1991): 24-79.
  26. Wang A. “Determination of thiols following their separation by CZE with amperometric detection at a carbon electrode”. Journal Pharmaceutical Biomedical Analysis 23 (2000): 429-436.
  27. Nikolić KK and Velasević KK. “Coulometric determination of methimazole”. Pharmazie 42 (1987): 698.
  28. Moretti G., et al. “Determination of thyreostatic residues in cattle plasma by high-performance liquid chromatography with ultraviolet detection”. Journal Chromatography B 616 (1993): 291-296.
  29. El-Bardicy MG., et al. “Determination of carbimazole and methimazole by first and third derivative spectrophotometry”. Spectroscopy Letter 24 (1991):1079-1095.
  30. Pinzauti S., et al. “Potentiometric titration of thiols, cationic surfactants and halides using a solid-state silver-silver sulphide electrode”. Journal Pharmaceutical Biomedical Analysis 1 (1983): 47-53.
  31. Aletrari M., et al. “Study of the British Pharmacopeia method on methimazole (thiamazole) content in carbimazole tablets”. Journal Pharmaceutical Biomedical Analysis 16 (1998): 785-792.
  32. Meulemans A., et al. “Determination of methimazole in plasma by high performance liquid chromatography”. Journal of Liquid Chromatography 2 (1980): 287-298.
  33. Floberg S., et al. “Determination of methimazole in plasma using gas chromatography-mass spectrometry after alkylation”. Journal Chromatography B:Biomedical Sciences and Applications 1 (1980): 63-70.
  34. Skellern GG., et al. “The pharmacokinetics of methimaole after oral administration of carbimazole and methimazole in hyperthyroid patients”. British Journal Clinical Pharmacology 9 (1980): 137-143.
  35. , et al. “Optimization of ion-pair based hollow fiber liquid phase microextraction (IP-HFLPME) with HPLC-UV for the determination of methimazole in biological samples and animal feed”. Journal of Separation Science 35.12 (2012).
  36. Zakrzewski R. “Determination of methimazole in urine with the iodine-azide detection system following separation by reverse-phase high performance liquid chromatography”. Journal of Chromatography B 869 (2008): 67-74.
  37. Kusinierek K and Bald E. “Determination of methimazole in urine by liquid chromatography”. Talanta5 (2007): 2121-2125.
  38. Ringhand HP and Rischel WA. “High pressure liquid chromatographic determination of propylthiouracil in human plasma”. Journal Pharmaceutical Sciences 68 (1979): 1461-1463.
  39. Connell GR., et al. “Selective liquid chromatographic assay for propylthiouracil in plasma”. Journal Chromatography A1 (1991): 310-314.
  40. Giles HG., et al. “High-performance liquid chromatographic determination of plasma propylthiouracil”. Journal Pharmaceutical Sciences11 (1979): 1459-1460.
  41. Ratliff CR., et al. “Serum propyithiouracil: determination by a direct colorimetric procedure”. Clinical Chemistry11 (1972): 1373-1375.
Citation: Chika J Mbah. “Graves’ Disease: Analytical Methods to Determine Antithyroid Therapeutic Agents in Biological Fluids”. EC Emergency Medicine and Critical Care 4.6 (2020): 119-124.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

November Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the November issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before December 13, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.